CL2009000815A1 - Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria. - Google Patents
Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria.Info
- Publication number
- CL2009000815A1 CL2009000815A1 CL2009000815A CL2009000815A CL2009000815A1 CL 2009000815 A1 CL2009000815 A1 CL 2009000815A1 CL 2009000815 A CL2009000815 A CL 2009000815A CL 2009000815 A CL2009000815 A CL 2009000815A CL 2009000815 A1 CL2009000815 A1 CL 2009000815A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- phenylhydroxymethylpyrrolidine
- beta
- pharmaceutical composition
- receptor agonist
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- XRIRRAZNVLMQOP-UHFFFAOYSA-N (2-phenylpyrrolidin-1-yl)methanol Chemical compound OCN1CCCC1C1=CC=CC=C1 XRIRRAZNVLMQOP-UHFFFAOYSA-N 0.000 title 1
- 206010020853 Hypertonic bladder Diseases 0.000 title 1
- 206010027566 Micturition urgency Diseases 0.000 title 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 title 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 title 1
- 208000020629 overactive bladder Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 108040005346 beta3-adrenergic receptor activity proteins Proteins 0.000 abstract 1
- 229940126214 compound 3 Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
COMPUESTO DERIVADO DE FENILHIDROXIMETILPIRROLIDINA DE FÓRMULA IA, O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, O UN ESTEREOISÓMERO DEL MISMO, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL ESTEREOISÓMERO DEL MISMO DONDE R3 Y N SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHO COMPUESTO Y UN VEHICULO FARMACÉUTICAMENTE ACEPTABLE; Y USO DE UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE DICHO COMPUESTO QUE SIRVE PARA PREPARAR UN MEDICAMENTO ÚTIL PARA EL TRATAMIENTO O PREVENCIÓN DE UNA ENFERMEDAD O TRASTORNO MEDIADO POR LA ACTIVACIÓN DEL ADRENOCEPTOR ß3 .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12306308P | 2008-04-04 | 2008-04-04 | |
US20604309P | 2009-01-27 | 2009-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000815A1 true CL2009000815A1 (es) | 2009-08-21 |
Family
ID=40671093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000815A CL2009000815A1 (es) | 2008-04-04 | 2009-04-03 | Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria. |
Country Status (38)
Country | Link |
---|---|
US (3) | US8399480B2 (es) |
EP (1) | EP2276756B9 (es) |
JP (3) | JP4783867B2 (es) |
KR (3) | KR101331771B1 (es) |
CN (2) | CN102056917B (es) |
AR (1) | AR072043A1 (es) |
AT (1) | ATE535521T1 (es) |
AU (1) | AU2009231714B2 (es) |
BR (1) | BRPI0909768B1 (es) |
CA (1) | CA2719876C (es) |
CL (1) | CL2009000815A1 (es) |
CO (1) | CO6331440A2 (es) |
CR (2) | CR11751A (es) |
CY (1) | CY1112552T1 (es) |
DO (2) | DOP2010000294A (es) |
EA (1) | EA020135B1 (es) |
EC (1) | ECSP10010518A (es) |
ES (1) | ES2376278T3 (es) |
GE (1) | GEP20125666B (es) |
HK (1) | HK1147099A1 (es) |
HN (1) | HN2010002030A (es) |
HR (1) | HRP20120129T2 (es) |
IL (1) | IL208215A (es) |
MA (1) | MA32257B1 (es) |
ME (1) | ME01988B (es) |
MX (1) | MX2010010929A (es) |
NI (1) | NI201000164A (es) |
NZ (1) | NZ588266A (es) |
PE (1) | PE20091825A1 (es) |
PL (1) | PL2276756T3 (es) |
PT (1) | PT2276756E (es) |
RS (1) | RS52175B (es) |
SG (1) | SG188883A1 (es) |
SI (1) | SI2276756T1 (es) |
SV (1) | SV2010003687A (es) |
TW (1) | TWI378098B (es) |
WO (2) | WO2009124167A1 (es) |
ZA (1) | ZA201006720B (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
WO2011025774A1 (en) * | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
NZ599233A (en) * | 2009-10-07 | 2013-04-26 | Merck Sharp & Dohme | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
AU2011245499B2 (en) * | 2010-04-30 | 2014-09-25 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
CA2805427A1 (en) * | 2010-07-23 | 2012-01-26 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
AU2011285928B9 (en) * | 2010-08-03 | 2018-08-02 | B3Ar Therapeutics, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
GB2484713A (en) | 2010-10-21 | 2012-04-25 | Optovate Ltd | Illumination apparatus |
EP2742030B1 (de) * | 2011-08-11 | 2016-07-27 | Bayer Intellectual Property GmbH | 1,2,4-triazolyl-substituierte ketoenole zum einsatz im pflanzenschutz |
JP6063948B2 (ja) | 2011-10-27 | 2017-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ベータ3アゴニストおよび中間体を製造するプロセス |
ES2584427T3 (es) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Proceso para la preparación de agonistas beta 3 y productos intermedios |
WO2013074650A1 (en) | 2011-11-18 | 2013-05-23 | Codexis, Inc. | Biocatalysts for the preparation of hydroxy substituted carbamates |
TW201338772A (zh) * | 2012-02-09 | 2013-10-01 | Altherx Inc | 藥學組合物 |
JP2015178458A (ja) * | 2012-07-25 | 2015-10-08 | 杏林製薬株式会社 | ベンゼン環縮合含窒素5員複素環式化合物、またはその薬理学的に許容される塩 |
US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
BR112015023328A2 (pt) | 2013-03-13 | 2017-07-18 | Flatley Discovery Lab | compostos de piridazinona e métodos para o tratamento de fibrose cística |
WO2014150639A1 (en) * | 2013-03-15 | 2014-09-25 | Merck Sharp & Dohme Corp. | Process for preparing beta 3 agonists and intermediates |
CN103232352B (zh) * | 2013-05-11 | 2015-12-23 | 苏州永健生物医药有限公司 | (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯 |
CN103760286A (zh) * | 2014-01-14 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | 一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法 |
WO2015191907A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
KR20170086659A (ko) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 |
KR20170103962A (ko) | 2015-01-20 | 2017-09-13 | 머크 샤프 앤드 돔 코포레이션 | 인자 xia 억제제 |
IL310527A (en) | 2015-10-23 | 2024-03-01 | B3Ar Therapeutics Inc | Zwitterion solvegron and its uses |
EP3463307A4 (en) * | 2016-06-03 | 2020-01-15 | Velicept Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS |
GB201705365D0 (en) | 2017-04-03 | 2017-05-17 | Optovate Ltd | Illumination apparatus |
GB201705364D0 (en) | 2017-04-03 | 2017-05-17 | Optovate Ltd | Illumination apparatus |
EP3630783A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | PENICILLIN BINDING PROTEIN INHIBITORS |
US20210077496A1 (en) | 2017-06-06 | 2021-03-18 | Urovant Sciences Gmbh | Dosing of vibegron for treatment of overactive bladder |
CN117695286A (zh) | 2017-06-06 | 2024-03-15 | 住友制药(苏州)有限公司 | 使用维贝隆以治疗膀胱过度活动症 |
GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
US11376253B2 (en) | 2017-12-21 | 2022-07-05 | Kyorin Pharmaceutical Co., Ltd. | Agent for treating nocturnal pollakiuria |
GB201800574D0 (en) | 2018-01-14 | 2018-02-28 | Optovate Ltd | Illumination apparatus |
GB201803767D0 (en) | 2018-03-09 | 2018-04-25 | Optovate Ltd | Illumination apparatus |
GB201807747D0 (en) | 2018-05-13 | 2018-06-27 | Optovate Ltd | Colour micro-LED display apparatus |
AU2019273837A1 (en) | 2018-05-23 | 2020-11-19 | Urovant Sciences Gmbh | Use of vibegron to treat pain associated with irritable bowel syndrome |
KR20210102892A (ko) | 2018-12-05 | 2021-08-20 | 유로반트 사이언시즈 게엠베하 | 과민성 방광 증상의 치료를 위한 비베그론 |
CN109503500A (zh) * | 2018-12-17 | 2019-03-22 | 天津药明康德新药开发有限公司 | 一种2-(2-氧代吡嗪-1(2h)-基)乙酸的合成方法 |
CN109734712B (zh) * | 2019-01-30 | 2020-10-20 | 广东东阳光药业有限公司 | 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途 |
AU2020243514A1 (en) | 2019-03-18 | 2021-08-26 | Urovant Sciences Gmbh | Use of vibegron to treat overactive bladder |
TW202102883A (zh) | 2019-07-02 | 2021-01-16 | 美商瑞爾D斯帕克有限責任公司 | 定向顯示設備 |
EP4018236A4 (en) | 2019-08-23 | 2023-09-13 | RealD Spark, LLC | DEVICE FOR DIRECTIONAL LIGHTING AND VISIBILITY DISPLAY |
EP4028804A4 (en) | 2019-09-11 | 2023-10-25 | RealD Spark, LLC | DEVICE FOR DIRECTIONAL LIGHTING AND VISIBILITY DISPLAY |
US11163101B2 (en) | 2019-09-11 | 2021-11-02 | Reald Spark, Llc | Switchable illumination apparatus and privacy display |
JP2022550540A (ja) | 2019-10-03 | 2022-12-02 | リアルディー スパーク エルエルシー | 受動光学ナノ構造を備える照明装置 |
JP2022550938A (ja) | 2019-10-03 | 2022-12-06 | リアルディー スパーク エルエルシー | 受動光学ナノ構造を含む照射装置 |
CN115136065A (zh) | 2020-02-20 | 2022-09-30 | 瑞尔D斯帕克有限责任公司 | 照明和显示设备 |
MX2023007413A (es) | 2020-12-22 | 2023-07-21 | Urovant Sciences Gmbh | Metodos para monitorear digoxina con el uso de vibegron para tratar veiiga hiperactiva. |
WO2022175848A1 (en) | 2021-02-16 | 2022-08-25 | Urovant Sciences Gmbh | Methods of treating heart failure with vibegron |
GB202113588D0 (en) | 2021-09-23 | 2021-11-10 | Atrogi Ab | New compounds and methods |
GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
CN115850286B (zh) * | 2022-12-05 | 2023-08-22 | 奥锐特药业(天津)有限公司 | 一种维贝格龙中间体及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
DOP2003000587A (es) * | 2002-02-27 | 2003-08-30 | Pfizer Prod Inc | AGONISTAS DEL RECEPTOR ß3-ADRENERGICO |
ATE500827T1 (de) * | 2002-11-07 | 2011-03-15 | Astellas Pharma Inc | Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff |
FR2874011B1 (fr) * | 2004-08-03 | 2007-06-15 | Sanofi Synthelabo | Derives de sulfonamides, leur preparation et leur application en therapeutique |
PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
-
2009
- 2009-03-27 PE PE2009000460A patent/PE20091825A1/es active IP Right Grant
- 2009-03-30 AR ARP090101127A patent/AR072043A1/es active IP Right Grant
- 2009-04-02 JP JP2010543320A patent/JP4783867B2/ja active Active
- 2009-04-02 NZ NZ588266A patent/NZ588266A/en unknown
- 2009-04-02 KR KR1020107024750A patent/KR101331771B1/ko active Protection Beyond IP Right Term
- 2009-04-02 GE GEAP200911992A patent/GEP20125666B/en unknown
- 2009-04-02 CN CN200980121149.2A patent/CN102056917B/zh active Active
- 2009-04-02 PL PL09726601T patent/PL2276756T3/pl unknown
- 2009-04-02 CN CN201110265670.2A patent/CN102391255B/zh active Active
- 2009-04-02 WO PCT/US2009/039253 patent/WO2009124167A1/en active Application Filing
- 2009-04-02 SI SI200930188T patent/SI2276756T1/sl unknown
- 2009-04-02 ES ES09726601T patent/ES2376278T3/es active Active
- 2009-04-02 US US12/936,221 patent/US8399480B2/en active Active
- 2009-04-02 SG SG2013017736A patent/SG188883A1/en unknown
- 2009-04-02 BR BRPI0909768A patent/BRPI0909768B1/pt active IP Right Grant
- 2009-04-02 US US12/417,239 patent/US8247415B2/en active Active
- 2009-04-02 WO PCT/US2009/039249 patent/WO2009124166A1/en active Application Filing
- 2009-04-02 AT AT09726601T patent/ATE535521T1/de active
- 2009-04-02 CA CA2719876A patent/CA2719876C/en active Active
- 2009-04-02 AU AU2009231714A patent/AU2009231714B2/en active Active
- 2009-04-02 MX MX2010010929A patent/MX2010010929A/es active IP Right Grant
- 2009-04-02 KR KR1020127015876A patent/KR101288798B1/ko not_active IP Right Cessation
- 2009-04-02 KR KR1020127026256A patent/KR20120118086A/ko not_active Application Discontinuation
- 2009-04-02 EP EP09726601A patent/EP2276756B9/en active Active
- 2009-04-02 RS RS20120042A patent/RS52175B/en unknown
- 2009-04-02 EA EA201071169A patent/EA020135B1/ru not_active IP Right Cessation
- 2009-04-02 PT PT09726601T patent/PT2276756E/pt unknown
- 2009-04-02 ME MEP-2012-549A patent/ME01988B/me unknown
- 2009-04-03 TW TW098111302A patent/TWI378098B/zh active
- 2009-04-03 CL CL2009000815A patent/CL2009000815A1/es unknown
-
2010
- 2010-07-14 JP JP2010159938A patent/JP5432846B2/ja active Active
- 2010-09-16 IL IL208215A patent/IL208215A/en active IP Right Grant
- 2010-09-20 ZA ZA2010/06720A patent/ZA201006720B/en unknown
- 2010-09-30 HN HN2010002030A patent/HN2010002030A/es unknown
- 2010-09-30 SV SV2010003687A patent/SV2010003687A/es unknown
- 2010-10-01 NI NI201000164A patent/NI201000164A/es unknown
- 2010-10-01 DO DO2010000294A patent/DOP2010000294A/es unknown
- 2010-10-04 EC EC2010010518A patent/ECSP10010518A/es unknown
- 2010-10-04 CO CO10122821A patent/CO6331440A2/es active IP Right Grant
- 2010-10-22 CR CR11751A patent/CR11751A/es unknown
- 2010-10-29 MA MA33292A patent/MA32257B1/fr unknown
-
2011
- 2011-02-02 HK HK11101147.7A patent/HK1147099A1/xx unknown
- 2011-05-13 JP JP2011107738A patent/JP4783870B1/ja active Active
-
2012
- 2012-02-07 HR HRP20120129AT patent/HRP20120129T2/hr unknown
- 2012-02-29 CY CY20121100209T patent/CY1112552T1/el unknown
- 2012-05-25 CR CR20120282A patent/CR20120282A/es unknown
- 2012-06-20 US US13/527,934 patent/US8653260B2/en active Active
-
2013
- 2013-11-15 DO DO2013000267A patent/DOP2013000267A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000815A1 (es) | Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria. | |
ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
CL2008000836A1 (es) | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. | |
AR117814A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
CL2012001366A1 (es) | Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras. | |
PE20090113A1 (es) | Compuestos triciclicos como moduladores del receptor de glucocorticoides, composiciones y procedimientos | |
PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
CO6390101A2 (es) | Compuestos purina | |
ECSP11011560A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
CR20120591A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
CL2008003789A1 (es) | Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer. | |
UY31554A1 (es) | Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus | |
CL2009000662A1 (es) | Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios. | |
AR070158A1 (es) | Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa | |
CL2007003289A1 (es) | Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam | |
AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato | |
UY31672A1 (es) | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
CL2011001050A1 (es) | Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros. | |
CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. |